PDE4 Phase III trial in IPF patients
Research payments
$9,314,358
Through program year 2025, $9,314,358 in research payments was reported against PDE4 Phase III trial in IPF patients, across 966 payments.
- Paid by (largest first)
- Boehringer Ingelheim Pharmaceuticals, Inc.; Boehringer Ingelheim International GmbH
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
4 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $21,029 | 438 |
| 2024 | Research | $3,335,788 | 189 |
| 2023 | Research | $5,706,515 | 206 |
| 2022 | Research | $251,026 | 133 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Claire McGroder New York, NY Named on 27 payments
- Reginald Fowler Winston-Salem, NC Named on 24 payments
- Barry Shea Boston, MA Named on 21 payments
- Gary Hunninghake Boston, MA Named on 20 payments
- Girish Nair Lexington, KY Named on 20 payments
- Francis Averill Clearwater, FL Named on 18 payments
- Mary Kreider Philadelphia, PA Named on 18 payments
- Mary Scholand Salt Lake City, UT Named on 18 payments
- Fortune Alabi Kissimmee, FL Named on 17 payments
- Alvaro Aranda Rodriguez Guaynabo, PR Named on 17 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.